[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Third Affiliated Hospital of Guangzhou Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":174},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,68,97,124,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100646308","maternal-inheritance-of-a-pathogenic-mt-nd1-mutation-causes-mitochondrial-dysfunction-and-spermatogenic-failure-in-men-100646308",false,"NCT07691827","Maternal Inheritance of a Pathogenic MT-ND1 Mutation Causes Mitochondrial Dysfunction and Spermatogenic Failure in Men","Study Protocol Used in Maternal Inheritance of a Pathogenic MT-ND1 Mutation Causes Mitochondrial Dysfunction and Spermatogenic Failure in Men","MTND1-INA\u002FC","Inclusion Criteria:\n\n* Men with idiopathic non-obstructive azoospermia or cryptozoospermia.\n* Male patients undergoing a clinically indicated testicular biopsy, testicular sperm aspiration (TESA), microdissection testicular sperm extraction (micro-TESE), or a related clinical procedure, when residual clinical specimens are available.\n* Comparison participants with normal spermatogenesis, including men with obstructive azoospermia and men undergoing sperm retrieval or testicular tissue evaluation for clinical reasons.\n* Selected relatives and spouses of enrolled patients, when needed for genetic segregation analysis and determination of variant origin.\n\nExclusion Criteria:\n\n* For the idiopathic non-obstructive azoospermia or cryptozoospermia cohort, azoospermia with an established alternative cause, including chromosomal abnormalities, Y-chromosome microdeletions, testicular tumors, severe trauma, prior radiotherapy or chemotherapy, or confirmed infection.\n* Incomplete clinical data or inability to obtain informed consent.\n* Biospecimens that do not meet quality requirements for the planned analyses.","ALL",{"count":19,"type":20},1200,"ESTIMATED","OBSERVATIONAL","Idiopathic non-obstructive azoospermia and cryptozoospermia are severe forms of male infertility in which sperm production is absent or extremely low and the cause is often unknown. This retrospective observational study examined whether mitochondrial DNA variants, particularly the MT-ND1 m.3700G\\>A variant, are associated with impaired sperm production in Chinese men.\n\nExisting clinical records and available biospecimens from affected men, eligible family members, and fertile controls were analyzed to assess familial inheritance patterns, the frequency of the variant, and its association with infertility phenotypes. No study-related treatment or intervention was provided to human participants.",[24,25],"Azoospermia, Nonobstructive","Cryptozoospermia",[27,28,29],"Male Infertility","MT-ND1","Maternal Inheritance","RECRUITING","2026-07-07",{"date":33,"type":34},"2026-07-09","ACTUAL",{"date":36,"type":34},"2021-04-01",{"date":38,"type":20},"2027-06-01",{"name":40,"class":41},"The Third Affiliated Hospital of Guangzhou Medical University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100633995","incidence-and-predictors-of-elevated-alt-in-postpartum-chb-mothers-100633995","NCT07533929","Incidence and Predictors of Elevated ALT in Postpartum CHB Mothers","Incidence and Predictors of Elevated Alanine Aminotransferase in Postpartum Chronic Hepatitis B Mothers","Inclusion Criteria:\n\nFemale; Between 20-40 years old; HBsAg positive for more than 6 months; ALT ≤40 U\u002FL; Any time point from 24 weeks of pregnancy to delivery; For HBV viral load \\>2x10\\^5 IU\u002Fml, regular TDF medication is required and should be stopped immediately after delivery; For HBV viral load \\\u003C2x10\\^5 IU\u002Fml, antiviral treatment is not needed; All patients should have good adherence.\n\nExclusion Criteria:\n\nAccompanied by hepatitis A, C, E viruses or other hepatotropic viral infections or AIDS; accompanied by cirrhosis, liver cancer, or other chronic liver diseases; accompanied by diseases of vital organs such as heart, lungs, or kidneys; accompanied by autoimmune hepatitis, autoimmune diseases, hypertension, diabetes, thyroid diseases; previous pregnancy with complications; previous pregnancy with fetal or neonatal growth and developmental defects; previous or current use of nephrotoxic drugs, glucocorticoids, cytotoxic drugs, or immunomodulators; ultrasound before medication indicates fetal malformations, abnormal fetal development, placental abnormalities, or threatened miscarriage; use of anti-hepatitis B virus drugs within six months before pregnancy; failure to follow up regularly according to the study plan.","FEMALE","20 Years","40 Years",{"count":54,"type":20},352,"China currently has about 86 million people with chronic hepatitis B virus infection, and infections caused by mother-to-child transmission account for 40% to 50% of new hepatitis B infections. Domestic and international guidelines both recommend that for pregnant women with high viral loads at 24-28 weeks of gestation, oral antiviral therapy should be administered based on a balance of risks and benefits and informed consent, continuing until after delivery, which can significantly reduce the rate of HBV mother-to-child transmission. Studies have reported that antiviral drugs such as tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) can reduce mother-to-child transmission rates in pregnant women with hepatitis B.\n\nIt has been reported that among pregnant women with hepatitis B infection and high viral loads but no obvious hepatitis, the incidence of postpartum hepatitis ranges from 15% to 35%. Among pregnant women who received antiviral therapy during pregnancy, 36.3% developed postpartum hepatitis. In a multicenter prospective randomized controlled trial (RCT), Pan and colleagues observed that the proportion of mothers with elevated ALT levels postpartum was 45% for those treated with tenofovir disoproxil fumarate (TDF) during pregnancy versus 30% for those untreated. A large retrospective cohort study involving 4,236 hepatitis B mothers in China found that the rate of postpartum ALT elevation in chronic hepatitis B pregnant women who did not receive antiviral therapy during pregnancy was 28.27%. This study also identified independent risk factors for postpartum ALT elevation, including high viral load during pregnancy. The peak periods of ALT elevation occurred between 4-6 weeks and 9-12 weeks postpartum, showing a bimodal distribution.\n\nTo explore the differences in prognosis between groups that did and did not receive antiviral therapy, we will conduct a prospective cohort study to assess the incidence of postpartum ALT elevation in mothers with chronic hepatitis B and identify independent risk factors that can predict postpartum ALT elevation. Our data will help healthcare providers better manage pregnant women with chronic hepatitis B.",[57,58],"Elevated Alanine Aminotransferase","Postpartum Chronic Hepatitis B Mothers","NOT_YET_RECRUITING","2026-04-09",{"date":62,"type":34},"2026-04-16",{"date":64,"type":20},"2026-08-01",{"date":66,"type":20},"2029-12-31",{"name":40,"class":41},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":50,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":5},"100594938","planned-delivery-at-37-versus-36-weeks-in-pregnancies-with-placenta-previaand-accreta-100594938","NCT07025954","Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta","Planned Delivery at 37 Versus 36 Weeks in Pregnancies Complicated byPlacenta Previa and Accreta: A Randomized Controlled Trial","Inclusion Criteria:\n\n* 28-34 weeks of gestation.\n* Both ultrasound and MRI indicate placenta previa with placenta accreta spectrum (PAS).\n* Planned to undergo cesarean delivery at the participating study hospitals.\n* Agree to participate and sign the informed consent form.\n\nExclusion Criteria:\n\n* Multiple gestation.\n* Other obstetric complications (e.g., preeclampsia, vasa previa), and severe maternal medical conditions (e.g., uncontrolled diabetes, progressive cardiovascular disease, active systemic lupus erythematosus, liver cirrhosis).\n* Major uterine structural anomalies (e.g., uterine didelphys, Uterine tumors ≥5 cm).\n* Estimated fetal weight \\\u003C3rd percentile for gestational age, major congenital anomalies, intrauterine fetal demise.","18 Years","45 Years",{"count":78,"type":20},600,"INTERVENTIONAL",[81],"NA","Current clinical practice guidelines recommend planned cesarean delivery(CD) at 34-37 weeks of gestation in pregnant women with placenta previa and accreta. Preterm birth may lead to neonatal immaturity, while laterCD may increase the risk of severe hemorrhage and surgery complications. Retrospective studies have shown that indicated CD occurs in approximately1\u002F3 of patients before 36 weeks, with the main trigger being antepartum hemorrhage. However, the risk of antepartum hemorrhage is lower after 36 weeks. Recent study showed that delivery shifted from 34-36 weeks to 37 weeks did not increase therisk of maternal intraoperative\u002Fpostoperative hemorrhage and emergency CD. To further validate this, we propose to conduct a randomized controlled study comparing the effect of planned delivery management strategies at 37 0\u002F7-37 6\u002F7 weeks of gestation with those at 36 0\u002F7-36 6\u002F7 weekson maternal and fetal outcomes. The aim of this study is to explore whether planned delivery up to 37 weeks in pregnant women with placenta previa and accreta improves neonatal outcomes without increasing maternal obstetric risks.",[84,85,86,87,88],"Placenta Previa","Placenta Accreta Spectrum","Antepartum Bleeding","Emergency Cesarean Section","Preterm Birth Complication","2025-07-11",{"date":91,"type":34},"2025-07-16",{"date":93,"type":34},"2025-07-12",{"date":95,"type":20},"2027-03-01",{"name":40,"class":41},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":50,"minAge":75,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":42},"100545588","the-project-of-gestational-hypertension-and-preeclampsia-screening-and-prevention-center-100545588","NCT06383858","The Project of Gestational Hypertension and Preeclampsia Screening and Prevention Center","The Project of Gestational Hypertension and Preeclampsia Screening and Prevention","Inclusion Criteria:\n\n* 1\\) Pregnant women who have been screened for pre-eclampsia risk according to the clinical risk factors listed in NICE guidelines (2019);\n* 2\\) Based on the authoritative guideline of Figo and the consensus of experts in China, pregnant women who routinely use maternal factor +MAP＋PLGF±UtA-PI in the first trimester or PLGF or sFlt-1\u002FPLGF in the second and third trimesters to assess the risk of preeclampsia.\n* 3\\) Meet any of the above conditions, join the group voluntarily, and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\) Severe fetal malformation or abnormality (no fetal heartbeat);\n* 2\\) Those who regularly use aspirin before joining the group;\n* 3\\) There are obvious other abnormal signs, laboratory tests or other clinical d• iseases, which are judged by the researcher to be not suitable for participating in researchers;\n* 4\\) Unable to obtain follow-up and delivery information.",true,{"count":106,"type":20},50000,"Preeclampsia is the main cause of illness and death in pregnant women and fetuses. Currently, there is no effective treatment for preeclampsia in clinical practice, and the fundamental treatment is still termination of pregnancy and placental delivery.\n\nTherefore, early prediction of preeclampsia and targeted strengthening of high-risk pregnant women supervision, early intervention and diagnosis and treatment can greatly reduce the serious obstetric complications and perinatal maternal and fetal deaths caused by preeclampsia, which has significant social and clinical significance.",[109,110],"Preeclampsia","Maternal Deaths",[109,112,113,114,115],"Placental growth factor (PlGF)","Real-World Study","Screening","Prevention","2024-09-05",{"date":118,"type":34},"2024-09-19",{"date":120,"type":34},"2023-08-01",{"date":122,"type":20},"2028-12-31",{"name":40,"class":41},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":50,"minAge":75,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":42},"100548394","dynamic-monitoring-of-ctdna-and-hpv-dna-in-plasma-for-the-early-prediction-of-recurrence-after-cervical-cancer-surgery-100548394","NCT06420427","Dynamic Monitoring of ctDNA and HPV DNA in Plasma for the Early Prediction of Recurrence After Cervical Cancer Surgery","Dynamic Monitoring of Circulating Tumor DNA (ctDNA) and HPV DNA in Plasma for the Early Prediction of Recurrence After Cervical Cancer Surgery\u002FTreatment","Inclusion Criteria:\n\n* Patients with newly diagnosed HPV-positive cervical malignancy at stages I-IV who have not undergone surgery, radiation therapy, or chemotherapy.\n* Patients must be older than 18 years of age.\n* Cervical cancer patients who are eligible for surgery and\u002For chemoradiotherapy.\n* Estimated life expectancy of more than three months.\n* Understands the study protocol and voluntarily participates in the research by signing the informed consent form.\n* Able to provide specimens and corresponding clinical information at each time point.\n\nExclusion Criteria:\n\n* Patients who are participating in other clinical trials.\n* Pregnant or breastfeeding women.\n* Patients with severe mental illness.\n* Patients who voluntarily withdraw.\n* Patients unable to complete the study protocol.",{"count":132,"type":20},150,"Assess the sensitivity, specificity, positive predictive value, and negative predictive value of dynamic monitoring of circulating tumor DNA (ctDNA) combined with circulating HPV DNA (cfHPV DNA) for early prediction of recurrence in cervical cancer post-surgery or post-treatment, and compare its advantages and disadvantages with existing diagnostic methods.",[135],"cfHPV DNA in Plasma of Cervical Cancer Patients",[137,138],"cfHPV DNA","cervical cancer","2024-05-14",{"date":141,"type":34},"2024-05-20",{"date":143,"type":34},"2024-01-01",{"date":145,"type":20},"2027-01-30",{"name":40,"class":41},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":42},"100529962","the-efficacy-of-vosevi-in-treating-daa-experienced-patients-100529962","NCT06180590","The Efficacy of Vosevi in Treating DAA-experienced Patients","A Prospective Cohort Study: the Efficacy of Vosevi in Treating Direct Antiviral Agent Therapy Failure Patients","Inclusion Criteria:\n\n* Age of 20-70 years.\n* Accepted the standard direct antiviral agent before\n* HCV-RNA still positive\n* Patients are administrated with once-daily oral Vosevi (Sofosbuvir\u002FVelpatasvir\u002FVoxilaprevir: 400mg\u002F100mg\u002F100mg) or Sofosbuvir\u002FVelpatasvir (400mg\u002F100mg) combined with ribavirin（500mg）twice a day treatment for rescue therapy.\n* The good compliance of patients.\n\nExclusion Criteria:\n\n* Patients with antibodies against HIV, HBV, HDV, concretion or other forms of infectious disease.\n* Evidence of hepatocellular carcinoma, decompensated liver disease, auto-immune hepatitis, or significant renal, cardiovascular, respiratory or neurological comorbidity.\n* Concurrent treatment with glucocorticoids, cytotoxic drugs, nonsteroidal anti-inflammatory drugs, or immune modulators.\n* Pregnancy.","70 Years",{"count":156,"type":20},200,"Hepatitis C virus (HCV) infection remains a significant health problem in our country. The World Health Organization estimated that 71 million people worldwide had chronic HCV infection in 2015. And 399,000 people died from cirrhosis or primary hepatocellular carcinoma caused by HCV infection. In 2006, the positive rate of HCV antibody in the population aged 1-59 was 0.43%. Therefore, it was estimated that there were about 5.6 million HCV infected people in the general population, and about 10 million cases of HCV infected people in high-risk groups and high incidence areas.\n\nUniversal genotype direct antiviral agent (DAA) is the preferred antiviral therapy for hepatitis C. Sofosbuvir\u002Fvelpatasvir are direct antiviral agents for hepatitis C. The results of Asian clinical trials mainly in Chinese population showed that the sustained virologic response (SVR) rates of sofosbuvir\u002Fvelpatasvir at 12 weeks in genotype 1a, 1b, 2, 3a, 3b and 6 were 100%, 100%, 100%, 95%, 76% and 99%, respectively. Limited data showed that the SVR rate of sofosbuvir\u002Fvelpatasvir at 12 weeks was 96% in Chinese genotype 3b patients without cirrhosis and 50% in patients with cirrhosis.\n\nAfter standard antiviral therapy for hepatitis C, there are still some patients who cannot obtain SVR, and these patients are defined as DAA-experienced patients. The guidelines recommend that Sofosbuvir\u002FVelpatasvir combined with ribavirin be used as salvage therapy for patients with DAA-experienced failure. Vosevi is a new generation of antiviral therapy for hepatitis C, which contains three components, (Sofosbuvir, Velpatasvir and Voxilaprevir. It was a salvage treatment plan for DAAs-experienced patients which was recommended by the Chinese hepatitis C prevention and treatment guidelines in 2019. However, there are insufficient data on the proportion of SVR acquired in Vosevi treated DAAs-experienced patients in Asian populations and the effectivity of antiviral therapy between Vosevi and Sofosbuvir\u002FVelpatasvir combined with ribavirin.\n\nIn the present study, the investigators enroll DAAs-experienced hepatitis C patients. The participants are randomly divided into two groups. Then the participants are treated with Vosevi or Sofosbuvir\u002FVelpatasvir combined with ribavirin respectively. All enrolled participants are followed-up for 3 years. Objectives of the present study are as follows:\n\nA. To clarify the sustained virologic response rate after Vosevi therapy for DAAs-experienced patients.\n\nB. To clarify the safety and efficacy between the Vosevi therapy and the Sofosbuvir\u002FVelpatasvir combined with ribavirin therapy.\n\nC. To clarify the changes of biochemistry indexes in DAAs-experienced patients after Vosevi therapy.\n\nD. To clarify the virological relapse rate at 12 weeks after Vosevi therapy. E. To clarify the rate of cirrhosis and liver cancer during the follow-up.",[159,160],"Chronic Hepatitis C","Medication Reaction",[162,163,164,165],"Vosevi","Efficacy","DAAs-experienced","Sustained Viral Response","2024-03-11",{"date":168,"type":34},"2024-03-13",{"date":170,"type":34},"2023-02-28",{"date":172,"type":20},"2027-02-28",{"name":40,"class":41},""]